Anti-tumor necrosis factor-alpha antibody limits heart failure in a transgenic model.

  title={Anti-tumor necrosis factor-alpha antibody limits heart failure in a transgenic model.},
  author={Toshiaki Kadokami and Carole S. Frye and Bonnie H. Lemster and Carrie L Wagner and Arthur M Feldman and Charles F McTiernan},
  volume={104 10},
BACKGROUND - Tumor necrosis factor (TNF)-alpha has been implicated in the pathophysiology of congestive heart failure. A strain of transgenic mice (TNF1.6) with cardiac-specific overexpression of TNF-alpha develop congestive heart failure. METHODS AND RESULTS To determine the effect of anti-TNF-alpha therapy in this model, we studied 3 groups: TNF1.6 mice treated with saline, wild-type mice treated with saline, and TNF1.6 mice treated with TNF-alpha neutralizing antibody (cV1q) from 6 to 12… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.


Publications citing this paper.
Showing 1-10 of 42 extracted citations

Cardiomyocyte death: mechanisms and translational implications

Cell Death and Disease • 2011
View 4 Excerpts
Highly Influenced

TNF-α- mediated-p38-dependent signaling pathway contributes to myocyte apoptosis in rats subjected to surgical trauma.

Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology • 2015

Cardiovascular disease in rheumatoid arthritis.

Rheumatic diseases clinics of North America • 2014
View 1 Excerpt


Publications referenced by this paper.
Showing 1-10 of 13 references

A randomized, double-blind, placebo-controlled trial of subcutaneous Etanercept (p75 soluble tumor necrosis factor: FC fusion protein) in the treatment of moderate to severe Crohn’s disease

W Sandborn, SB Hanauer, S Katz
Gastroenterology • 2001

Similar Papers

Loading similar papers…